American Heart Association-Allen Initiative in Brain Health and Cognitive Impairment
Together with the American Heart Association, the Frontiers Group supports three large-scale, multidisciplinary research teams who are merging research of the brain and the blood vessels to develop new understanding of — and ultimately better preventions and treatments for — age-related brain disorders such as Alzheimer’s disease.
Through the American Heart Association-Allen Initiative in Brain Health and Cognitive Impairment, launched in 2018, these two organizations have committed $43 million to fund innovative approaches in combating age-related cognitive decline.
As people live longer in many parts of the world, Alzheimer’s and other age-related dementias are on the rise, projected to reach more than 75 million people worldwide by 2030. To date, no effective therapy has been developed for these disorders, which are not only deadly, but also exact a high financial and emotional toll on society.
AHA-Allen Initiative Team co-led by Tony Wyss-Coray, Ph.D., & Marion Buckwalter, M.D., Ph.D.
These researchers are delving into the molecular secrets that make young blood different from old, and whether those molecules could protect against age-related brain diseases.
AHA-Allen Initiative Team led by Rusty Gage, Ph.D.
This interdisciplinary group is exploring the idea that brain aging and cognitive decline are caused by a failure of interconnected systems in our bodies that trigger a domino-like cascade of disease.
AHA-Allen Initiative Team led by Mukesh K. Jain, M.D.
This collaborative group is studying how red blood cells and the lining of blood vessels work together as a unit to keep our brains healthy, and whether new therapies could keep them functioning for longer.